KAMADA LTD
No SEC Form 4 filings for $KMDA in the last 30 days.
See all $KMDA insider activity →Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.
Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.
Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.
Over the past 7 days, alphai's AI scored 2 news stories mentioning KMDA (KAMADA LTD). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent KMDA coverage spans financial news, earnings and technology.
Guidance plus a committed U.S. plasma supply contract supports near-term revenue visibility, while M&A remains the key upside lever.
Results and guidance reiteration support a bullish near-term bias, while the new plasma supply agreement adds visibility into 4Q26 revenue ramp.
The contract provides a defined, multi-year revenue stream tied to Kamada’s Texas plasma collection centers, with first commercial recognition expected in Q4 2026.
Conference-poster data supports CYTOGAM’s clinical value proposition in a high-risk lung transplant subgroup, potentially improving utilization expectations.
Kamada's strong FY25 revenue growth, increased net income, and reaffirmed 2026 guidance suggest positive momentum. The company's discounted valuation, biosimilars expansion, and solid balance sheet support a favorable outlook. The announcement of a new dividend policy further signals confidence in future earnings.
alphai scores every news story that mentions KMDA with an AI model for sentiment and relevance, and aggregates insider trades from KAMADA LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.
Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.
6 min readKamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.
6 min readKamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.
2 min readKamada (NASDAQ: KMDA) said three posters at the 2026 ISHLT meeting presented analyses of CYTOGAM (CMV immune globulin) in CMV high-risk lung transplant recipients. A retrospective review linked CYTOGAM prophylaxis with better clinical outcomes, paired blood-cell data showed reduced innate immune activation, and a non-clinical model reported blunted lung injury and improved mortality.
4 min readKamada (KMDA) reported strong FY25 revenue growth and increased net income, despite missing Q4 consensus estimates. Management reaffirmed robust 2026 guidance and announced a new annual dividend policy, signaling confidence in future growth. The company trades at a discounted valuation, with biosimilars expansion and a strong balance sheet supporting its investment appeal.
4 min readKamada's shares saw a decline following the announcement that the company has halted its Phase 3 study of an inhaled Alpha-1 Antitrypsin (AAT) therapy. The decision to stop the clinical trial is a significant setback for the development of this particular AAT treatment.
3 min readKamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
3 min readWhile the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
3 min readImage source: The Motley Fool.Monday, Nov. 10, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
5 min readHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 min read
